Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

The Valuation of Foley Trasimene Acquisition II Is Reasonable

By Thomas Niel, InvestorPlace Contributor

Based on the transaction details, there's room for BFT stock to gain in the years following its merger with Paysafe.

9 Great Dividend Stocks with 3%+ Yields

By Thomas Niel, InvestorPlace Contributor

Which dividend stocks should you consider for both 3%+ yields and the potential for appreciation? These nine names come to mind. Cardinal Health (NYSE:CAH) Conagra Brands (NYSE:CAG) IBM (NYSE:IBM) Kellogg (NYSE:K) Kimberly-Clark (NYSE:KMB) Lockheed Martin (NYSE:LMT) Pfizer (NYSE:PFE) Phillip Morris International (NYSE:PM) PPL Corporation (NYSE:PPL)

Despite the Reddit Rebound, Stay Away From GameStop Shares

By Thomas Niel, InvestorPlace Contributor

However, those buying in today are more likely than not getting in too late. With the risk this second round ends before it begins, steer clear of GME stock for now.

All Bets are Off Whether Zomedica Stock Grows Into Its Valuation

By Thomas Niel, InvestorPlace Contributor

In the meantime, the company still needs to execute the commercialization of Truforma. If it experiences any hiccups along the way, shares could fall back to lower price levels. Reconsider ZOM stock as a buy if that happens. But, for now, hold off buying.

Buy Star Peak Energy on Any Pullback Ahead of Its Stem Deal

By Thomas Niel, InvestorPlace Contributor

A sell-off in "green wave" stocks may send STPK stock lower. Seize that opportunity as long as the deal to buy Stem is still pending.

Load More